Characteristic | Patients with PMN (n = 186) |
---|---|
Baseline | |
Age at biopsy (years) | 49.1 ± 13.4 |
Male (n, %) | 102 (54.8) |
SCr (μmol/L) | 68.9 ± 22.5 |
eGFR (ml/min/1.73 m2) | 100.8 ± 20.7 |
Urea (mmol/L) | 5.6 ± 2.2 |
Alb (g/L) | 28.4 ± 19.1 |
UA (μmol/L) | 362.0 ± 95.5 |
24 h-u-pro (g/d) | 4.17 (2.31,7.34) |
SBP (mmHg) | 128.4 ± 15.2 |
DBP (mmHg) | 78.5 ± 11.0 |
Hypertension (n, %) | 47 (25.3) |
Follow-up | |
SCr (μmol/L) | 92.4 ± 89.1 |
eGFR (ml/min/1.73 m2) | 90.6 ± 29.9 |
Urea (mmol/L) | 6.6 ± 3.2 |
Alb (g/L) | 36.4 ± 8.5 |
UA (μmol/L) | 373.3.0 ± 106.6 |
24 h-u-pro (g/d) | 0.86 (0.15,2.65) |
Follow-up time (month) | 18.6 (6.7,45.5) |
Endpoint event (n,%) | 41 (22.0) |
Therapy | |
Corticosteroid monotherapy (n,%) | 29 (15.6) |
Immunosuppression (n,%) | 112 (60.2) |
Non- Immunosuppression (n,%) | 45 (24.2) |
Treatment effect | |
Corticosteroid monotherapy | |
CR/PR/non-SR (n,%) | 12/6/11 (41.4, 20.7, 37.9) |
Immunosuppression | |
CR/PR/non-SR (n,%) | 37/21/54 (33.0, 18.8, 48.2) |
Non- Immunosuppression | |
CR/PR/non-SR (n,%) | 14/13/18 (31.1, 28.9, 40.0) |